Long-term Efficacy
Continuation phase results for up to 2 years for DURATION- 1, DURATION-2, and DURATION-3 have been published. Analyses of these continuation phase data indicate that improvements in glycemic parameters and weight loss are maintained over the long term. At 2 years, mean change from baseline in A1C was –1.7% and in FPG – 40.1 mg/dL; 60% of patients maintained an A1C less than 7%. Although a small increase in weight was observed after 26 weeks, weight loss was maintained and at 2 years was approximately a 2-kg reduction from baseline. Results from 3-year data are preliminary, but suggest that improvements in glycemic control and weight loss are maintained at this timepoint.